

VU Research Portal

Glucocorticoid sensitivity in multiple sclerosis; what makes the difference?

van Winsen, L.M.L.

2009

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

van Winsen, L. M. L. (2009). *Glucocorticoid sensitivity in multiple sclerosis; what makes the difference?* [PhD-Thesis - Research and graduation internal, S.I.]. s.n.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl



Contents

Chapter 1	General introduction and outline of this thesis	9
Chapter 2	Glucocorticoid sensitivity in MS	25
Chapter 2.1	Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis	27
Chapter 2.2	The impact of glucocorticoid receptor gene polymorphisms on glucocorticoid sensitivity is outweighed in patients with multiple sclerosis	39
Chapter 3	Clinical implications of differences in GC sensitivity	49
Chapter 3.1	Suppressive effect of glucocorticoids on TNF- α production is associated with their clinical effect in multiple sclerosis	51
Chapter 3.2	Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS.	57
Chapter 3.3	A glucocorticoid receptor gene haplotype (TthIII1/ER22/23EK/9beta) is associated with a more aggressive disease course in multiple sclerosis	67
Chapter 4	Measurement of treatment effect after IV Methylprednisolone treatment	75
Chapter 4.1	Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in MS	77
Chapter 4.2	Outcome measurement in multiple sclerosis detection of clinically relevant improvement	87
Chapter 5	Discussion	99
	References	113
	Summary	127
	Samenvatting	135
	Dankwoord	143
	Curriculum vitae	149
	List of publications	152

